Search research articles
Contact Us
Filters
Showing results (211-220 of 237) with videos related to
Page
of 24
Sort By:
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 9, 2020
Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective
Irina Tsibulak, Elisabeth Reiser, Gerhard Bogner, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium
Nicole Concin, Ioana Braicu, Pierre Combe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Cancer Research
|
October 3, 2007
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Shahab Akhoondi, Dahui Sun, Natalie von der Lehr, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 13, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 5, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 237) with videos related to
Sort By:
Page
of 24
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 9, 2020
Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective
Irina Tsibulak, Elisabeth Reiser, Gerhard Bogner, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium
Nicole Concin, Ioana Braicu, Pierre Combe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Cancer Research
|
October 3, 2007
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Shahab Akhoondi, Dahui Sun, Natalie von der Lehr, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 13, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 5, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Page
of 24